Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center
Authors:
- Nadia HindiNadia Hindi
- Irene Carrasco GarcíaIGIrene Carrasco García
- Alberto Sánchez-CamachoASAlberto Sánchez-Camacho
- Antonio GutierrezAGAntonio Gutierrez
- Javier PeinadoJPJavier Peinado
- Inmaculada RincónIRInmaculada Rincón
- Johanna BenedettiJBJohanna Benedetti
- Pilar SanchoPSPilar Sancho
- Paloma SantosPSPaloma Santos
- Paloma Sánchez-BustosPSPaloma Sánchez-Bustos
- David MarcillaDMDavid Marcilla
- Victor EncinasVEVictor Encinas
Open Access
Abstract
Symptomatic control and tumoral shrinkage is an unmet need in advanced soft-tissue sarcoma (STS) patients beyond first-line. The combination of trabectedin and radiotherapy showed activity in a recently reported clinical trial in this setting. This retrospective series aims to analyze our experience with the same regimen in the real-life setting. We retrospectively reviewed advanced sarcoma patients treated with trabectedin concomitantly with radiotherapy with palliative intent. Growth-modulation index (GMI) was calculated as a surrogate of efficacy. Forty metastatic patients were analyzed. According to RECIST, there was one (2.5%) complete response, 12 (30%) partial responses, 18 (45%) disease stabilizations, and nine (22.5%) progressions. After a median follow-up of 15 months (range 2–38), median progression-free survival (PFS) and overall survival (OS) were 7.5 months (95% CI 2.8–12.2) and 23.5 months (95% CI 1.1–45.8), respectively. Median GMI was 1.42 (range 0.19–23.76), and in 16 (53%) patients, it was >1.33. In patients with GMI >1.33, median OS was significantly longer than in those with GMI 0–1.33 (median OS 52.1 months (95% CI not reached) vs. 8.9 months (95% CI 6.3–11.6), p = 0.028). The combination of trabectedin plus radiotherapy is an active therapeutic option in patients with advanced STS, especially when tumor shrinkage for symptomatic relief is needed.Keywords
This publication has 32 references indexed in Scilit:
- Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapyAnnals of Oncology, 2012
- Randomized Multicenter and Stratified Phase II Study of Gemcitabine Alone Versus Gemcitabine and Docetaxel in Patients with Metastatic or Relapsed Leiomyosarcomas: A Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study)The Oncologist, 2012
- Symptom Burden, Survival and Palliative Care in Advanced Soft Tissue SarcomaSarcoma, 2011
- Radiation Therapy for Palliation of Sarcoma Metastases: A Unique and Uniform Hypofractionation ExperienceSarcoma, 2010
- Resection of Pulmonary and Extrapulmonary Sarcomatous Metastases Is Associated With Long-Term SurvivalThe Annals of Thoracic Surgery, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- In vitro radiosensitisation by trabectedin in human cancer cell linesEuropean Journal of Cancer, 2008
- Role of homologous recombination in trabectedin-induced DNA damageEuropean Journal of Cancer, 2008
- Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002Journal of Clinical Oncology, 2007
- Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine ProductionCancer Research, 2005